| (USD) | Jun 2026 | Y/Y change |
|---|---|---|
| Revenue | 214.00M | — |
| Operating expense | — | — |
| Net income | -92.00M | — |
| Net profit margin | — | — |
| Earnings per share | — | — |
| EBITDA | — | — |
| Effective tax rate | — | — |
Over the past year, RARE returned -13.3% with dividends reinvested.
| Period | Total return |
|---|---|
| YTD | +12.3% |
| 1 year | -13.3% |
| 5 years | -73.2% |
| 10 years | -60.8% |
| All-time high | $141.54 (Feb 2021) |
Returns are total returns and include reinvested dividends. The all-time high is the highest monthly closing price on record.
See what $1,000 in RARE would be worth today ›No. Ultragenyx Pharmaceutical Inc. has not paid a dividend in the past 12 months.
Ultragenyx Pharmaceutical Inc. stock trades on NASDAQ under the ticker symbol RARE.
Ultragenyx Pharmaceutical Inc. is part of the Healthcare sector.
Ultragenyx Pharmaceutical Inc. has a market cap of 2.55B USD, based on the latest quote.
Ultragenyx Pharmaceutical Inc. is expected to report earnings around Nov 3, 2026. That date is an estimate and has not been confirmed by the company.
